Anterior cingulate Glutamate-Glutamine cycle metabolites are altered in euthymic bipolar I disorder

European Neuropsychopharmacology

Volumn 25, Issue 12, 2015, Pages 2221-2229

  Soeiro de Souza, Márcio Gerhardt ^a   Henning, Anke ^c,d   Machado Vieira, Rodrigo ^b   Moreno, Ricardo A ^a   Pastorello, Bruno F ^a   da Costa Leite, Cláudia ^a   Vallada, Homero ^a   Otaduy, Maria Concepcion Garcia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c ETH ZURICH   (Switzerland)

^d MAX PLANCK INSTITUTE FOR BIOLOGICAL CYBERNETICS   (Germany)

Author keywords

Bipolar; GABA; Glutamate; Glutamine; Spectroscopy

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; LITHIUM; VALPROIC ACID;

ADULT; AMINO ACID METABOLISM; ANTERIOR CINGULATE; ARTICLE; BIPOLAR I DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUTAMATERGIC SYNAPSE; GRAY MATTER; HUMAN; MALE; NEUROIMAGING; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; WHITE MATTER; ADOLESCENT; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; CINGULATE GYRUS; DRUG EFFECTS; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; GLUTAMINE; GYRUS CINGULI; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MASS SPECTROMETRY; MIDDLE AGED; YOUNG ADULT;

EID: 84951289913     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.09.020     Document Type: Article

References (64)

1. Abdallah C.G., et al. Glutamate Metabolism in Major Depressive Disorder. The American journal of psychiatry 2014, 171(12):1320-1327.
2. Berrettini W.H., Nurnberger J.I., Hare T.A., Simmons-Alling S., Gershon E.S. CSF GABA in euthymic manic-depressive patients and controls. Biol. Psychiatry 1986, 21:844-846.
3. Bhagwagar Z., Wylezinska M., Jezzard P., Evans J., Ashworth F., Sule A., Matthews P.M., Cowen P.J. Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol. Psychiatry 2007, 61:806-812. 10.1016/j.biopsych.2006.08.048.
4. Brady R.O., McCarthy J.M., Prescot A.P., Jensen J.E., Cooper A.J., Cohen B.M., Renshaw P.F., Ongur D. Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder. Bipolar Disord 2013, 15(4):434-439.
5. Brennan B.P., Hudson J.I., Jensen J.E., McCarthy J., Roberts J.L., Prescot A.P., Cohen B.M., Pope H.G., Renshaw P.F., Ongur D. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 2010, 35:834-846. 10.1038/npp.2009.191.
6. Cavassila S., Deval S., Huegen C., van Ormondt D., Graveron-Demilly D. Cramér-Rao bounds: an evaluation tool for quantitation. NMR Biomed. 2001, 14:278-283.
7. Colla M., Schubert F., Bubner M., Heidenreich J.O., Bajbouj M., Seifert F., Luborzewski A., Heuser I., Kronenberg G. Glutamate as a spectroscopic marker of hippocampal structural plasticity is elevated in long-term euthymic bipolar patients on chronic lithium therapy and correlates inversely with diurnal cortisol. Mol. Psychiatry 2009, 14:696-704. 647. 10.1038/mp.2008.26.
8. Cotter D.R., Pariante C.M., Everall I.P. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res. Bull. 2001, 55:585-595.
9. DSM-IV, P.A.T.F.O. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 2000, American Psychiatric Publishing, Inc., Washington, D.C.
10. Eastwood S.L., Harrison P.J. Markers of glutamate synaptic transmission and plasticity are increased in the anterior cingulate cortex in bipolar disorder. Biol. Psychiatry 2010, 67:1010-1016. 10.1016/j.biopsych.2009.12.004.
11. Fan T. Metabolite profiling by one- and two-dimensional NMR analysis of complex mixtures. Prog. Nucl. Magn. Reson. Spectrosc. 1996, (28):161-219.
12. Fatemi S.H., Hossein Fatemi S., Stary J.M., Earle J.A., Araghi-Niknam M., Eagan E. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67kDa and Reelin proteins in cerebellum. Schizophr. Res. 2005, 72:109-122. 10.1016/j.schres.2004.02.017.
13. First M.B., Spitzer R.L., Williams J.B. Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I 1996, American Psychiatric Press, Washington, DC.
14. +-dependent release in intractable depression assessed antemortem. Brain Res. 1989, 494:315-324.
15. Freeman M.P., Stoll A.L. Mood stabilizer combinations: a review of safety and efficacy. Am. J. Psychiatry 1998, 155:12-21.
16. Frye M.A., Tsai G.E., Huggins T., Coyle J.T., Post R.M. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol. Psychiatry 2007, 61:162-166. 10.1016/j.biopsych.2006.01.024.
17. Fuchs A., et al. ProFit revisited. Magnetic resonance in medicine: official journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine 2013, 71(2):458-468.
18. Garcia M., Huppertz H.-J., Ziyeh S., Buechert M., Schumacher M., Mader I. Valproate-induced metabolic changes in patients with epilepsy: assessment with H-MRS. Epilepsia 2009, 50:486-492. 10.1111/j.1528-1167.2008.01801.x.
19. Gasparovic C., Song T., Devier D., Bockholt H.J., Caprihan A., Mullins P.G., Posse S., Jung R.E., Morrison L.A. Use of tissue water as a concentration reference for proton spectroscopic imaging. Magn. Reson. Med. 2006, 55:1219-1226. 10.1002/mrm.20901.
20. Gerner R.H., Fairbanks L., Anderson G.M., Young J.G., Scheinin M., Linnoila M., Hare T.A., Shaywitz B.A., Cohen D.J. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am. J. Psychiatry 1984, 141:1533-1540.
21. Godlewska B.R., Yip S.W., Near J., Goodwin G.M., Cowen P.J. Cortical glutathione levels in young people with bipolar disorder: a pilot study using magnetic resonance spectroscopy. Psychopharmacology 2014, 231:327-332. 10.1007/s00213-013-3244-0.
22. Govindaraju V., Young K., Maudsley A.A. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000, 13:129-153.
23. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatr. 1960, 23:56-62.
24. Igarashi H., Kwee I.L., Nakada T., Katayama Y., Terashi A. 1H magnetic resonance spectroscopic imaging of permanent focal cerebral ischemia in rat: longitudinal metabolic changes in ischemic core and rim. Brain Res. 2001, 907:208-221.
25. Iltis I., Koski D.M., Eberly L.E., Nelson C.D., Deelchand D.K., Valette J., Ugurbil K., Lim K.O., Henry P.-G. Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized (1)H MRS study. NMR Biomed. 2009, 22:737-744. 10.1002/nbm.1385.
26. Jensen J.E., Licata S.C., Ongur D., Friedman S.D., Prescot A.P., Henry M.E., Renshaw P.F. Quantification of J-resolved proton spectra in two-dimensions with LCModel using GAMMA-simulated basis sets at 4 T. NMR Biomed. 2009, 22:762-769. 10.1002/nbm.1390.
27. Kaiser L.G., Young K., Meyerhoff D.J., Mueller S.G., Matson G.B. A detailed analysis of localized J-difference GABA editing: theoretical and experimental study at 4 T. NMR Biomed. 2008, 21:22-32. 10.1002/nbm.1150.
28. Kato T. Mitochondrial dysfunction bipolar disorder. Bipolar Disord. 2011, 5:187-200. 10.1007/7854_2010_52.
29. Kaufman R.E., Ostacher M.J., Marks E.H., Simon N.M., Sachs G.S., Jensen J.E., Renshaw P.F., Pollack M.H. Brain GABA levels in patients with bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:427-434. 10.1016/j.pnpbp.2008.12.025.
30. Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., Epperson C.N., Goddard A., Mason G.F. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry 2002, 7:S71-S80. 10.1038/sj.mp.4001021.
31. Levine J., Panchalingam K., Rapoport A., Gershon S., McClure R.J., Pettegrew J.W. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol. Psychiatry 2000, 47:586-593.
32. Levy L.M., Degnan A.J. GABA-based evaluation of neurologic conditions: MR spectroscopy. AJNR Am. J. Neuroradiol. 2013, 34:259-265. 10.3174/ajnr.A2902.
33. Machado-Vieira R., Manji H.K., Zarate C.A. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009, 15:525-539. 10.1177/1073858409336093.
34. Machado-Vieira R., Salvadore G., Ibrahim L.A., Diaz-Granados N., Zarate C.A. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr. Pharm. Des. 2009, 15:1595-1611.
35. Maddock R.J., Buonocore M.H. MR spectroscopic studies of the brain in psychiatric disorders. Curr. Top. Behav. Neurosci 2012, 199-251. 10.1007/7854_2011_197.
36. Martinez-Hernandez A., Bell K.P., Norenberg M.D. Glutamine synthetase: glial localization in brain. Science 1977, 195:1356-1358.
37. Mlynárik V., Gruber S., Moser E. Proton T (1) and T (2) relaxation times of human brain metabolites at 3 T. NMR Biomed. 2001, 14:325-331.
38. Mlynárik V., Kohler I., Gambarota G., Vaslin A., Clarke P.G.H., Gruetter R. Quantitative proton spectroscopic imaging of the neurochemical profile in rat brain with microliter resolution at ultra-short echo times. Magn. Reson. Med. 2008, 59:52-58. 10.1002/mrm.21447.
39. Ongur D., Jensen J.E., Prescot A.P., Stork C., Lundy M., Cohen B.M., Renshaw P.F. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol. Psychiatry 2008, 64:718-726. 10.1016/j.biopsych.2008.05.014.
40. Ongür D., Drevets W.C., Price J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl. Acad. Sci. USA 1998, 95:13290-13295.
41. Provencher S.W.S. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993, 30:672-679. 10.1002/mrm.1910300604.
42. Quiroz J.A., Gray N.A., Kato T., Manji H.K. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008, 33:2551-2565. 10.1038/sj.npp.1301671.
43. Rothman D.L., De Feyter H.M., de Graaf R.A., Mason G.F., Behar K.L. 13C MRS studies of neuroenergetics and neurotransmitter cycling in humans. NMR Biomed. 2011, 24:943-957. 10.1002/nbm.1772.
44. Sanacora G. Do glutamatergic agents represent a new class of antidepressant drugs? Part 1. J. Clin. Psychiatry 2009, 70:1473-1475. 10.4088/JCP.09ac05680blu.
45. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 2008, 7:426-437. 10.1038/nrd2462.
46. Schulte R.F., Boesiger P. ProFit: two-dimensional prior-knowledge fitting of J-resolved spectra. NMR Biomed. 2006, 19:255-263. 10.1002/nbm.1026.
47. Schulte R.F., Lange T., Beck J., Meier D., Boesiger P. Improved two-dimensional J-resolved spectroscopy. NMR Biomed. 2006, 19:264-270. 10.1002/nbm.1027.
48. Senaratne R., Milne A.M., MacQueen G.M., Hall G.B.C. Increased choline-containing compounds in the orbitofrontal cortex and hippocampus in euthymic patients with bipolar disorder: a proton magnetic resonance spectroscopy study. Psychiatry Res. 2009, 172:205-209. 10.1016/j.pscychresns.2008.07.007.
49. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):S22-S33. quiz 34-57.
50. Shen J. Glutamate. Magnetic Resonance Spectroscopy: Tools for Neuroscience Research and Emerging Clinical Applications 2014, Academic Press, Elsevier Inc, San Diego, CA, USA. C.J. Stagg, D.L. Rothman (Eds.).
51. Shen J., Petersen K.F., Behar K.L., Brown P., Nixon T.W., Mason G.F., Petroff O.A., Shulman G.I., Shulman R.G., Rothman D.L. Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proc. Natl. Acad. Sci. USA 1999, 96:8235-8240.
52. Smith, S.A., Levante, T.O., de Beer, R., Luyten, P.R., van Ormondt, D., 1994. Computer simulations in magnetic resonance. An object-oriented programming approachapproach, J. Magn. Reson. A (106), 75-105.
53. Soeiro de Souza M.G., Salvadore G., Moreno R.A., Otaduy M.C.G., Chaim K.T., Gattaz W.F., Zarate C.A., Machado-Vieira R. Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder. Neuropsychopharmacology 2013, 38:468-475. 10.1038/npp.2012.203.
54. Stork C., Renshaw P.F. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol. Psychiatry 2005, 10:900-919. 10.1038/sj.mp.4001711.
55. Théberge J., Al-Semaan Y., Williamson P.C., Menon R.S., Neufeld R.W.J., Rajakumar N., Schaefer B., Densmore M., Drost D.J. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am. J. Psychiatry 2003, 160:2231-2233.
56. Théberge J., Bartha R., Drost D.J., Menon R.S., Malla A., Takhar J., Neufeld R.W., Rogers J., Pavlosky W., Schaefer B., Densmore M., Al-Semaan Y., Williamson P.C. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatry 2002, 159:1944-1946.
57. Tkác I., Starcuk Z., Choi I.Y., Gruetter R. In vivo 1H NMR spectroscopy of rat brain at 1ms echo time. Magn. Reson. Med. 1999, 41:649-656.
58. Torrey E.F., Barci B.M., Webster M.J., Bartko J.J., Meador-Woodruff J.H., Knable M.B. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol. Psychiatry 2005, 57:252-260. 10.1016/j.biopsych.2004.10.019.
59. van der Veen J.W., de Beer R., Luyten P.R., van Ormondt D. Accurate quantification of in vivo 31P NMR signals using the variable projection method and prior knowledge. Magn. Reson. Med. 1988, 6:92-98.
60. Waagepetersen H.S., Sonnewald U., Schousboe A. Glutamine, glutamate, and GABA: metabolic aspects. Handbook of Neurochemistry and Molecular Neurobiology: Amino Acids and Peptides in the Nervous System 2007, 1-21. Springer, New York. A. Lajtha, S. Oja, A. Schousboe, P. Saransaari (Eds.).
61. Wang P.W., Sailasuta N., Chandler R.A., Ketter T.A. Magnetic resonance spectroscopy measurement of cerebral gamma-aminobutyric acid concentrations in patients with bipolar disorders. Acta Neuropsychiatr. 2006, 18:120-126.
62. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 1978, 133:429-435.
63. Yüksel C., Ongur D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol. Psychiatry 2010, 68:785-794. 10.1016/j.biopsych.2010.06.016.
64. Zhang Y., Brady M., Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans. Med. Imaging 2001, 20:45-57. 10.1109/42.906424.